Swiss pharma giant Roche is refocusing its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- , (Nasdaq: TVTX) ...

Zurich, Switzerland - Amcor plc (NYSE: AMCR; ASX: AMC) will announce its First Quarter 2025 results for the three months ...

The global natural vanillin market is anticipated to experience substantial growth, with a compound annual growth rate (CAGR) ...

This explains why Switzerland is now launching ... And Switzerland wants to exploit this potential. As for the pharmaceutical industry – Switzerland’s largest exporter – it has saved only ...

That is why SCHOTT Pharma designs solutions grounded in science ... developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for ...

That is why SCHOTT Pharma designs solutions grounded in science to ensure ... With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company ...

That is why SCHOTT Pharma designs solutions grounded in science to ensure ... With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company ...

Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ...

Doug E. Frantz has been appointed the new vice chancellor for innovation and commercialization at Washington University in St ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...